Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q-Reference-Cited by-同舟云学术

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q

Published:2016-08-10 Issue:11 Volume:95 Page:1805-1810
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Balaian Ekaterina,Schuster Claudia,Schönefeldt Claudia,Germing Ulrich,Haase Detlef,Tuve Sebastian,Ordemann Rainer,Ehninger Gerhard,Bornhäuser Martin,Oelschlaegel Uta,Mohr Brigitte,von Bonin Malte,Platzbecker Uwe,Wermke Martin

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2775-y.pdf

Reference32 articles.

1. Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S, Longinotti M (2009) Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 37(8):947–955. doi: 10.1016/j.exphem.2009.04.009

2. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25(12):1075–1083

3. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 120(4):679–684

4. Rothstein DM, Camirand G (2015) New insights into the mechanisms of Treg function. Curr Opin Organ Transplant 20(4):376–384. doi: 10.1097/MOT.0000000000000212

5. Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK (2012) Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 189(6):3198–3208. doi: 10.4049/jimmunol.1200602

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance;Journal of Personalized Medicine;2023-02-25

2. Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report;The Tohoku Journal of Experimental Medicine;2023

3. Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases;Journal of Oncology Pharmacy Practice;2021-09-30

4. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy;British Journal of Haematology;2020-02-03

5. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients;Blood Cancer Journal;2019-08